Bellicum Pharmaceuticals, Inc.

The emerging pipeline of CAR-T in NHL includes late-stage, mid-stage, and early-stage drugs in different lines of therapies and different indications, mainly including B- cell Lymphoma such as DLBCL, FL, MCL, MZL, CLL/SLL, and others, with one of them being developed for a T-cell Lymphoma, PTCL. LAS VEGAS, April 15, 2024 /PRNewswire/ -- DelveInsight's CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Insights report includes a comprehensive understanding of current treatment practices, CAR T-Cell Therapy for NHL emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan]. Key Takeaways from the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Report According to DelveInsight's analysis, the market size for CAR T-Cell therapy for NHL reached USD 1,200 million in 2023 across the US. DelveInsight's analysis reveals that the total incident cases of selected indications for CAR-T in NHL in the 7MM comprised ~155,200 in 2023. Leading CAR T-Cell therapy for NHL companies such as Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Mustang Bio, CRISPR Therapeutics, 2seventy Bio, Imugene, and others are developing novel CAR T-Cell therapies for NHL drugs that can be available in the CAR T-Cell therapy for NHL market in the coming years. Other promising CAR T-Cell therapies for NHL in the pipeline include Cemacabtagene Ansegedleucel, Rapcabtagene Autoleucel, Zamtocabtagene Autoleucel, MB-106, CTX110, BBT369, Azercabtagene Zapreleucel , and others. BREYANZI is poised to dominate the CAR-T market in NHL in the forthcoming years, with potential approvals anticipated across two indications: CLL/SLL, follicular lymphoma and MCL. Notably, it has already secured approval for DLBCL in 3L+, 2L+ TE, and NTE. Novartis is progressing with its additional CD-19 CAR-T therapy, Rapcabtagene autoleucel, with expectations of a significantly reduced turnaround time for availability compared to KYMRIAH. Companies are leveraging the strength of dual and triple targeting in CAR-T therapies. Miltenyi Biomedicine, ImmPACT Bio, 2seventy bio, and Novartis are developing CD19/20 Bispecific CAR-T, CD79a/CD20 Bispecific CAR-T, and CD2xCD3xCD19 CAR-T, enhancing treatment efficacy by targeting multiple antigens simultaneously. Discover which therapies are expected to grab the major CAR T-Cell therapy for NHL market share @ CAR T-Cell Therapy for NHL Market Report CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Overview CAR-T cell therapy represents a groundbreaking advancement in cancer immunotherapy, especially for specific types of NHL that have shown resistance to traditional therapies. Through the manipulation of genetically modified T cells, this state-of-the-art treatment boosts the immune system's capacity to locate and eliminate cancerous cells. Essentially, CAR-T cell therapy modifies a patient's T cells genetically to carry chimeric antigen receptors (CARs) on their surface. These engineered CARs are tailored to identify and attach to particular proteins found on cancer cells' surfaces, thereby directing the immune system to effectively combat the malignancy. CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Epidemiology Segmentation In 2023, DLBCL had the highest number of cases among all selected indications for CAR-T therapy, followed by Follicular lymphoma. The total incident cases of MZL in the 7MM were around 13,800 in 2023 and are projected to increase during the forecasted period. The CAR T-Cell therapy for NHL market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Incident Cases of Selected Indications for CAR-T in NHL (Mantle cell lymphoma, DLBCL, Follicular lymphoma, Marginal Zone Lymphoma, Primary mediastinal large B-cell lymphoma, Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma) and Total Indication-wise Eligible Cases of CAR-T in NHL. CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Treatment Market The treatment landscape for NHL is complex, influenced by factors such as the type of NHL, the stage of the disease, the patient's overall health, and their preferences. CAR-T cell therapy has emerged as a promising option within this landscape, especially for aggressive B-cell NHLs that have not responded to standard treatments. Previously, such cases posed significant challenges, often resulting in poor outlooks despite attempts with salvage chemotherapy and autologous stem cell transplants. However, the introduction of CAR-T cell therapy has drastically changed this scenario, showing impressive response rates and the potential for long-lasting remissions even in patients with advanced disease after multiple prior treatments. The approval of various CAR-T therapies for NHL by the FDA highlights the importance of this advancement. YESCARTA, KYMRIAH, BREYANZI, and TECARTUS have all proven effective across different types of NHL, including DLBCL, follicular lymphoma, and mantle cell lymphoma. Ongoing research aims to improve CAR-T cell therapy for NHL further, seeking to increase effectiveness, decrease side effects, and expand the range of target antigens beyond CD19. Additionally, studies are looking into the combined use of CAR-T cell therapy with other treatments like checkpoint inhibitors or targeted therapies, with the ultimate goal of optimizing treatment outcomes for NHL patients. To know more about CAR T-Cell therapy for Non-Hodgkin's Lymphoma treatment guidelines, visit @ CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Management Emerging CAR T-Cell Therapies for NHL and Key Companies Cemacabtagene Ansegedleucel: Allogene Therapeutics Rapcabtagene Autoleucel: Novartis Zamtocabtagene Autoleucel: Miltenyi Biomedicine MB-106: Mustang Bio CTX110: CRISPR Therapeutics BBT369: 2seventy Bio Azercabtagene Zapreleucel: Imugene Learn more about the FDA-approved CAR T-Cell therapy for NHL @ Drugs for CAR T-Cell Therapy for NHL Treatment CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Dynamics The dynamics of the CAR T-Cell therapy for the NHL market are expected to change in the coming years. The market for CAR T-cell therapy in NHL is characterized by a surge in research and development activities, as pharmaceutical companies race to bring new therapies to the market. With several CAR T-cell therapies receiving FDA approval, competition among manufacturers is intense, driving innovation and investment in the field. As a result, we witness a dynamic landscape with ongoing clinical trials, collaborations, and strategic partnerships aiming to expand the reach and efficacy of CAR T-cell therapies for NHL. Moreover, the market dynamics of CAR T-cell therapy for NHL are influenced by patient accessibility and reimbursement challenges. Despite the remarkable efficacy of these therapies, their high cost poses a significant barrier to widespread adoption. Healthcare systems and insurers grapple with the economic implications of CAR T-cell therapy, leading to negotiations on pricing and reimbursement models. Efforts are underway to make these life-saving treatments more accessible to patients, including discussions on value-based pricing and outcome-based reimbursement. As the field continues to evolve, the CAR T-cell therapy for NHL market dynamics will be shaped by a delicate balance between the clinical benefits of CAR T-cell therapy and the economic considerations surrounding its widespread implementation in the treatment of Non-Hodgkin's lymphoma. Scope of the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Report Therapeutic Assessment: CAR T-Cell Therapy for Non-Hodgkin's Lymphoma current marketed and emerging therapies CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Dynamics: Key Market Forecast Assumptions of Emerging CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Access and Reimbursement Discover more about CAR T-Cell therapy for NHL drugs in development @ CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Clinical Trials Table of Contents Related Reports CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Pipeline CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CAR T-Cell therapy for NHL companies, including Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Mustang Bio, CRISPR Therapeutics, 2seventy Bio, Imugene, among others. CAR T-Cell Therapy Market CAR T-Cell Therapy Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy companies, including CytoAgents, Genentech, Incyte Corporation, Caribou Biosciences, Chimeric Therapeutics, Allogene Therapeutics, Kyverna Therapeutics, iCell Gene Therapeutics, Synthekine, Janssen Research & Development, SecuraBio, ImmPACT Bio, A2 Biotherapeutics, Gracell Biopharmaceuticals, Wugen, Sana Biotechnology, Oncternal Therapeutics, Vor Biopharma, CARsgen Therapeutics, Autolus Limited, Arcellx, Kite, Novartis, Lyell Immunopharma, ImmPACT Bio, Tmunity Therapeutics, Poseida Therapeutics, Precigen, AffyImmune Therapeutics, 2seventy bio, Takeda, Cartesian Therapeutics, Cabaletta Bio, Legend Biotech, Miltenyi Biomedicine, Beam Therapeutics, among others. CAR T-Cell Therapy Competitive Landscape CAR T-cell Therapy Competitive Landscape – 2024 report provides comprehensive insights about the pipeline and current landscape, pipeline and marketed drug profiles, and the key CAR T-cell therapy companies, including Alnylam Pharmaceuticals, JW Therapeutics, Gilead Sciences, Janssen Pharmaceuticals, Innovent Biologics, Sorrento Therapeutics, Cartesian Therapeutics, CASI Pharmaceuticals, Juventas Cell Therapy, Novartis, Poseida Therapeutics,Shanghai Unicar-Therapy Bio-medicine Technology, Sinobioway Cell Therapy, Tessa Therapeutics, Wuhan Bio-Raid Biotechnology, Miltenyi Biomedicine, Bristol-Myers Squibb, Autolus Limited, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Cellular Biomedicine Group, Chongqing Precision Biotech, Eureka Therapeutics, Formula Pharmaceuticals, Guangzhou Bio-gene Technology, Hebei Senlang Biotechnology, Mustang Bio, MolMed, Aurora BioPharma, Atara Biotherapeutics, Autolus, Bellicum Pharmaceuticals, Kecellitics Biotech Company, Yake Biotechnology, Minerva Biotechnologies, Allogene Therapeutics, PersonGen BioTherapeutics (Suzhou), Precision BioSciences, Pregene (ShenZhen) Biotechnology Company, Shanghai GeneChem, Shanghai Longyao Biotechnology, Shenzhen BinDeBio, among others. CAR T-Cell Therapy for Multiple Myeloma Market CAR T-Cell Therapy for Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CAR T-cell therapy for multiple myeloma companies, including Cartesian Therapeutics, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen Therapeutics, Poseida Therapeutics, Juno Therapeutics, CRISPR Therapeutics, bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Celyad Oncology, Allogene Therapeutics, Gadeta, Nanjing IASO Biotherapeutics, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

Artios Strengthens Board of Directors with Appointment of RTW Investments’ Chris Liu, Ph.D.CAMBRIDGE, United Kingdom and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Chris Liu, Ph.D., Senior Research Analyst specializing in oncology at RTW Investments, LP (“RTW”), to its Board of Directors. Niall Martin, Chief Executive Officer of Artios, said: “We are delighted to welcome Chris, a prominent research analyst to our Board of Directors. His deep knowledge of the oncology therapeutic landscape and breadth of relationships within the investment community will be invaluable as we further advance our robust DDR pipeline.” In February 2024, RTW Biotech Opportunities Ltd, a New York-based investment firm focused on the life sciences sector entered into an agreement to acquire London-based biotechnology venture capital firm Arix Bioscience PLC. Through the acquisition, RTW acquired Arix’s portfolio, of which Artios was a large equity position. Chris Liu, Ph.D. Board Director of Artios, added: “RTW is now a top shareholder of Artios following the acquisition of Arix and the expansion of our equity interest, which reflects both our confidence and excitement in Artios’ innovative platform targeting broad aspects of the DNA damage response. I look forward to partnering with the team and the Board to support them in their mission to bring new therapies to patients suffering from difficult to treat solid tumors.” Chris Liu, Ph.D. brings over 10 years of financial and biotechnology experience, specializing in oncology therapeutics across diverse indications, technology platforms and stages of development. He currently serves as a Senior Research Analyst at RTW where he leads oncology research on biotechnology companies and covers life sciences companies in China. Prior to joining RTW, Chris spent 5 years in Business Development at GenScript, where his work focused on antibody drug discovery and development including novel immuno-oncology targets. He also helped design and optimize chimeric antigen receptor (CAR) constructs for CAR-T cell therapy companies such as Kite, Juno, and Bellicum. Chris received a Ph.D. in Biochemistry from SUNY Stony Brook and a B.S. in Chemistry from Fudan University. He also received his Master of Business Administration (MBA) in Finance and Management from NYU Stern School of Business. He currently serves on the board of NiKang Therapeutics, Oricell Therapeutics and Nuance Pharma as a Board Director or Observer. About Artios Artios is on a mission to kill cancer by exploiting DNA damage response (DDR) and repair pathways that are leveraged by cancer cells to promote their survival. Our specialized DcoDeR platform integrates Artios’ leadership capabilities, expertise and experience in DNA damage biology and drug discovery to systematically discover and develop medicines targeting the totality of the DDR. We have built an extensive DDR focused pipeline designed to address areas of high unmet needs across solid tumour indications including our ATR inhibitor, ART0380, and our Polθ inhibitor, ART6043, as monotherapies and with combination treatments. Together with our strategic partnerships with Merck KGaA and Novartis, and research collaborations with premiere institutions like Cancer Research UK, The Institute of Cancer Research, The Netherlands Cancer Institute, and the Crick Institute we are pioneering validated approaches to DDR drug discovery. Visit our website at https://www.artios.com/ for more information about the company and our pipeline. For more information about Artios Pharma Ltd., please contact: Investor Relations and Media Contact:Tim McCarthyLifeSci Advisorstim@lifesciadvisors.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/896a2ebc-4a5f-46ec-9416-a58c89b02db9

CAMBRIDGE, United Kingdom and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Chris Liu, Ph.D., Senior Research Analyst specializing in oncology at RTW Investments, LP (“RTW”), to its Board of Directors. Niall Martin, Chief Executive Officer of Artios, said: “We are delighted to welcome Chris, a prominent research analyst to our Board of Directors. His deep knowledge of the oncology therapeutic landscape and breadth of relationships within the investment community will be invaluable as we further advance our robust DDR pipeline.” In February 2024, RTW Biotech Opportunities Ltd, a New York-based investment firm focused on the life sciences sector entered into an agreement to acquire London-based biotechnology venture capital firm Arix Bioscience PLC. Through the acquisition, RTW acquired Arix’s portfolio, of which Artios was a large equity position. Chris Liu, Ph.D. Board Director of Artios, added: “RTW is now a top shareholder of Artios following the acquisition of Arix and the expansion of our equity interest, which reflects both our confidence and excitement in Artios’ innovative platform targeting broad aspects of the DNA damage response. I look forward to partnering with the team and the Board to support them in their mission to bring new therapies to patients suffering from difficult to treat solid tumors.” Chris Liu, Ph.D. brings over 10 years of financial and biotechnology experience, specializing in oncology therapeutics across diverse indications, technology platforms and stages of development. He currently serves as a Senior Research Analyst at RTW where he leads oncology research on biotechnology companies and covers life sciences companies in China. Prior to joining RTW, Chris spent 5 years in Business Development at GenScript, where his work focused on antibody drug discovery and development including novel immuno-oncology targets. He also helped design and optimize chimeric antigen receptor (CAR) constructs for CAR-T cell therapy companies such as Kite, Juno, and Bellicum. Chris received a Ph.D. in Biochemistry from SUNY Stony Brook and a B.S. in Chemistry from Fudan University. He also received his Master of Business Administration (MBA) in Finance and Management from NYU Stern School of Business. He currently serves on the board of NiKang Therapeutics, Oricell Therapeutics and Nuance Pharma as a Board Director or Observer. About Artios Artios is on a mission to kill cancer by exploiting DNA damage response (DDR) and repair pathways that are leveraged by cancer cells to promote their survival. Our specialized DcoDeR platform integrates Artios’ leadership capabilities, expertise and experience in DNA damage biology and drug discovery to systematically discover and develop medicines targeting the totality of the DDR. We have built an extensive DDR focused pipeline designed to address areas of high unmet needs across solid tumour indications including our ATR inhibitor, ART0380, and our Polθ inhibitor, ART6043, as monotherapies and with combination treatments. Together with our strategic partnerships with Merck KGaA and Novartis, and research collaborations with premiere institutions like Cancer Research UK, The Institute of Cancer Research, The Netherlands Cancer Institute, and the Crick Institute we are pioneering validated approaches to DDR drug discovery. Visit our website at for more information about the company and our pipeline. For more information about Artios Pharma Ltd., please contact: Investor Relations and Media Contact: Tim McCarthy LifeSci Advisors tim@lifesciadvisors.com A photo accompanying this announcement is available at Chris Liu, Ph.D. Chris Liu, Ph.D., Senior Research Analyst specializing in oncology at RTW Investments, LP, was appointed to Artios' Board of Directors